

11/815,269

10/596,740 has overlapping scope with 11/815,269.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bvx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 6 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 9 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 12 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 18 JUL 28 EPFULL enhanced with additional legal status
information from the EPOline Register
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20 JUL 28 STN Viewer performance improved
NEWS 21 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 24 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 25 AUG 25 CA/CAPLUS, CASREACT, and IFI and USPAT databases
enhanced for more flexible patent number searching
CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 27 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued

11/815,269

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:21:49 ON 24 SEP 2008

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:22:02 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\11815269.str

11/815,269



```
chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
5-8 6-7 8-9 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
6-7 9-10
exact bonds :
5-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:22:26 FILE 'REGISTRY'

11/815,269

SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 768 TO 1712
PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> d scan

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Acetamide, N-[3-[2-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-
5-pyrimidinyl]ethynyl]phenyl]-2-(methylsulfonyl)-
MF C28 H22 Cl F N4 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-
MF C20 H17 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2,4-Imidazolidinedione, 5-[2-[4-amino-2-(4-thiomorpholinyl)-5-pyrimidinyl]ethynyl]-5-[(1,3-dihydro-6-methoxy-1-oxo-2H-isindol-2-yl)methyl]-, (5R)-

MF C23 H23 N7 O4 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-
[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]-

MF C29 H26 Cl F N4 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl-


MF C27 H22 Cl F N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11/815,269


L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-
MF C18 H15 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanimidamide, N'-[5-[2-(4-chlorophenyl)ethynyl]-4-[(4-
ME hydroxyphenyl)amino]-2-pyrimidinyl]-N,N-bis(1-methylethyl)-
C25 H26 Cl N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Acetamide, N-[6-[2-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-

5-pyrimidinyl]ethynyl]-2-pyridinyl]-

MF C26 H19 Cl F N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Urea, N-[3-[2-[4-[2-(dimethylamino)ethyl]amino]-5-

pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]-

MF C24 H29 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11/815,269

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Cyclohexanol, 4-[[2-amino-5-[2-(4-ethylphenyl)ethynyl]-4-
pyrimidinyl]amino]-, trans-
MF C20 H24 N4 O
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

11/815,269

=> s l1 sss ful

FULL SEARCH INITIATED 16:22:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1462 TO ITERATE

100.0% PROCESSED 1462 ITERATIONS

305 ANSWERS

SEARCH TIME: 00.00.01

L3

305 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 16:22:57 ON 24 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13

FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4

31 L3


=> d l4 1-31 bib hitstr

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:829030 CAPLUS
 DN 149:153106
 TI Preparation of HIV inhibiting 5,6-substituted pyrimidines
 IN Guillemont, Jerome Emile Georges; Mordant, Celine Isabelle; Schmitt, Benoit Antoine
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 51pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008080965	A2	20080710	WO 2007-EP64606	20071228
	WO 2008080965	A3	20080904		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	EP 2006-127328	A	20061229		
OS	MARPAT 149:153106				
IT	1037452-93-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of HIV inhibiting 5,6-substituted pyrimidines)				
RN	1037452-93-9 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-6-(methoxymethyl)-5-[2-(3-pyridinyl)ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)				

Double bond geometry as shown.


11/815,269




L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:265796 CAPLUS
 DN 149:118634
 TI Construction of pharmacophore model of EGFR TK inhibitor
 AU Chen, Xi; Liu, Xin-Xia; Huang, Hui; Hu, Hui-Hui; Jiang, Feng-Chao
 CS School of Pharmacy, Tongji Medical College, Huazhong Science and
 Technology University, Wuhan, 430030, Peop. Rep. China
 SO Wuli Huaxue Xuebao (2008), 24(2), 281-288
 CODEN: WHXUEU; ISSN: 1000-6818
 PB Wuli Huaxue Xuebao Bianjibu
 DT Journal
 LA Chinese
 IT 845657-23-0 845657-38-7 845657-48-9
 845657-53-6 845657-57-0 845657-82-1
 845658-03-9 845658-12-0 845658-25-5
 887147-46-8 887147-49-1 887147-50-4
 887147-51-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (construction of pharmacophore model of EGFR TK inhibitor)
 RN 845657-23-0 CAPLUS
 CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-
 pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-38-7 CAPLUS
 CN 4-Pyrimidinamine, 5-[2-(3-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-
 fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845657-48-9 CAPLUS
 CN 4-Pyrimidinamine, 5-[2-(4-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-
 fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845657-53-6 CAPLUS

CN Acetamide, N-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)




RN 845657-57-0 CAPLUS

CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-82-1 CAPLUS

CN 2-Pyridinemethanol, 6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845658-03-9 CAPLUS

CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845658-12-0 CAPLUS

CN Urea, N-[6-[2-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl- (CA INDEX NAME)




RN 845658-25-5 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(2-amino-4-pyrimidinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 887147-46-8 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(2-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 887147-49-1 CAPLUS

CN Benzamide, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-N-methyl- (CA INDEX NAME)



RN 887147-50-4 CAPLUS


CN Propanamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-3-(methylsulfonyl)- (CA INDEX NAME)



RN 887147-51-5 CAPLUS

CN Pentanoic acid, 5-[[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]amino]-5-oxo-, methyl ester (CA INDEX NAME)


11/815,269




L4 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1293176 CAPLUS
 DN 148:144965
 TI Synthesis and DNA Incorporation of an Ethynyl-Bridged Cytosine
 C-Nucleoside as Guanosine Surrogate
 AU Heinrich, Daniel; Wagner, Thomas; Diederichsen, Ulf
 CS Institut fuer Organische und Biomolekulare Chemie, Universitaet
 Goettingen, Goettingen, D-37077, Germany
 SO Organic Letters (2007), 9(25), 5311-5314
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 148:144965
 IT 1000889-69-9D, partially self-complementary duplex
 RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation,
 nonpreparative)
 (asym. synthesis of ethynyl-bridged cytosine C-nucleoside
 phosphoramidite via Sonogashira cross coupling of iodocytosine with
 ethynyl deoxyribose, as guanosine surrogate of DNA in the study of
 duplex stability)
 RN 1000889-69-9 CAPLUS
 CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-
 (3'→5')-2'-deoxycytidylyl-(3'→5')-1'-de(6-amino-9H-purin-9-
 yl)-2'-deoxy-1'-[2-[6-[(dimethylamino)methylene]amino]-1,2-dihydro-2-oxo-
 5-pyrimidinyl]ethynyladenylyl-(3'→5')-2'-deoxycytidylyl-
 (3'→5')-2'-deoxy- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (asym. synthesis of ethynyl-bridged cytosine C-nucleoside
 phosphoramidite via Sonogashira cross coupling of iodocytosine with
 ethynyl deoxyribose, as guanosine surrogate of DNA in the study of
 duplex stability)

IT 1000889-54-2P 1000889-62-2P 1000889-64-4P

1000889-66-6P 1000889-68-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(asym. synthesis of ethynyl-bridged cytosine C-nucleoside)


phosphoramidite via Sonogashira cross coupling of iodocytosine with ethynyl deoxyribose, as guanosine surrogate of DNA in the study of duplex stability)

RN 1000889-54-2 CAPLUS

CN D-ribo-Hept-1-ynitol, 3,6-anhydro-7-O-[bis(4-methoxyphenyl)phenylmethyl]-1,2,4-trideoxy-1-[6-[(dimethylamino)methylene]amino]-1,2-dihydro-2-oxo-5-pyrimidinyl]-, 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 1000889-62-2 CAPLUS

CN D-erythro-Hept-1-ynitol, 1-(6-amino-1,2-dihydro-2-oxo-5-pyrimidinyl)-3,6-anhydro-1,2,4-trideoxy-5,7-bis-O-[(1,1-dimethylethyl)dimethylsilyl]-, (3E)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000889-64-4 CAPLUS

CN D-ribo-Hept-1-ynitol, 1-(6-amino-1,2-dihydro-2-oxo-5-pyrimidinyl)-3,6-anhydro-1,2,4-trideoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000889-66-6 CAPLUS

CN D-ribo-Hept-1-ynitol, 1-(6-amino-1,2-dihydro-2-oxo-5-pyrimidinyl)-3,6-anhydro-7-O-[bis(4-methoxyphenyl)phenylmethyl]-1,2,4-trideoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 1000889-68-8 CAPLUS

CN D-ribo-Hept-1-ynitol, 3,6-anhydro-7-O-[bis(4-methoxyphenyl)phenylmethyl]-1,2,4-trideoxy-1-[6-[[[(dimethylamino)methylene]amino]-1,2-dihydro-2-oxo-5-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:814060 CAPLUS
 DN 147:211876
 TI Hydantoin derivatives for the treatment of inflammatory disorders and their preparation
 IN Lavey, Brian J.; Kozlowski, Joseph A.; Zhou, Guowei; Tong, Ling; Yu, Wensheng; Wong, Michael K. C.; Shankar, Bandarpalle B.; Shih, Neng-Yang; Siddiqui, M. Arshad; Rosner, Kristin E.; Dai, Chaoyang; Popovici-Muller, Janeta; Girijavallabhan, Vinay M.; Li, Dansu; Rizvi, Razia; Chen, Lei; Yang, De-Yi; Feltz, Robert; Kim, Seong-Heon
 PA Schering Corporation, USA
 SO PCT Int. Appl., 294pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007084451	A1	20070726	WO 2007-US1025	20070116
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007207707	A1	20070726	AU 2007-207707	20070116
	US 20070197564	A1	20070823	US 2007-653511	20070116
	US 20070265299	A1	20071115	US 2007-653798	20070116
PRAI	US 2006-759300P	P	20060117		
	WO 2007-US1025	W	20070116		
OS	MARPAT 147:211876				
IT	944717-89-9P 944717-95-7P 944718-00-7P				
	944718-01-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of hydantoin derivs. for treatment of inflammatory disorders and other diseases)				
RN	944717-89-9 CAPLUS				
CN	2,4-Imidazolidinedione, 5-[2-(4-amino-5-pyrimidinyl)ethynyl]-5-[(1,3-dihydro-6-methoxy-1-oxo-2H-isoindol-2-yl)methyl]-, (5R)- (CA INDEX NAME)				


Absolute stereochemistry.



RN 944717-95-7 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-(4-amino-2,3-dihydro-2-oxo-5-pyrimidinyl)ethynyl]-5-[(1,3-dihydro-6-methoxy-1-oxo-2H-isoindol-2-yl)methyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 944718-00-7 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-[4-amino-2-(4-thiomorpholinyl)-5-pyrimidinyl]ethynyl]-5-[(1,3-dihydro-6-methoxy-1-oxo-2H-isoindol-2-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 944718-01-8 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-(4-amino-2-chloro-5-pyrimidinyl)ethynyl]-5-[(1,3-dihydro-6-methoxy-1-oxo-2H-isoindol-2-yl)methyl]-, (5R)- (CA INDEX NAME)

11/815,269


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:647193 CAPLUS
 DN 147:64552
 TI Heterocyclic compound superoxide dismutase inhibitors for modulation of neurodegenerative diseases
 IN Benjamin, Daniel E.; Henrie, Robert N.; Errico, Monica A.; Rex, Brian T.; Bracken, Justin D.; Scott, Sean
 PA Alsgen, Inc., USA
 SO U.S. Pat. Appl. Publ., 27pp., Cont.-in-part of U.S. Ser. No. 365,462. CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070135437	A1	20070614	US 2006-605170	20061128
US 20060211645	A1	20060921	US 2006-365462	20060301
WO 2008067389	A2	20080605	WO 2007-US85776	20071128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-658505P	P	20050304		
US 2006-365462	A2	20060301		
US 2006-605170	A	20061128		
OS MARPAT 147:64552				
IT 223672-43-3				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Heterocyclic compound superoxide dismutase inhibitors for modulation of neurodegenerative diseases)				
RN 223672-43-3 CAPLUS				
CN 2,4-Pyrimidinediamine, 6-methyl-5-(2-phenylethynyl)-			(CA INDEX NAME)	



11/815,269

L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:386122 CAPLUS
DN 148:93054
TI Wide spectrum modulation by KP-544 in models relevant for neuronal survival
AU Geist, Marie A.; Volbracht, Christiane; Podhorna, Jana; Falsig, Jeppe; Leist, Marcel
CS Department of Disease Biology, H. Lundbeck A/S, Valby, Den.
SO NeuroReport (2007), 18(6), 571-575
CODEN: NERPEZ; ISSN: 0959-4965
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 393856-87-6, KP-544
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wide spectrum modulation by KP-544 in models relevant for neuronal survival)
RN 393856-87-6 CAPLUS
CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

11/815,269

L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:259817 CAPLUS

DN 146:316930

TI Preparation of substituted heteroaryl nitriles as cysteine protease inhibitors for treatment of malaria

IN Coteron Lopez, Jose Miguel; Fernandez Velando, Esther Pilar; Fiandor Roman, Jose Maria

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 170pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007025776	A2	20070308	WO 2006-EP8580	20060831
	WO 2007025776	A3	20070503		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	EP 2005-381043	A	20050902		
	EP 2006-110666	A	20060303		
OS	MARPAT 146:316930				
IT	929015-50-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of substituted heteroaryl nitriles as cysteine protease inhibitors for treatment of malaria)				
RN	929015-50-9 CAPLUS				
CN	Hydrazinecarboxylic acid, 2-[2-cyano-5-[2-[4-(trifluoromethyl)phenyl]ethynyl]-4-pyrimidinyl]-2-(2-methylpropyl)-, 1,1-dimethylethyl ester				
	2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)				

CM 1

CRN 929015-49-6

CMF C23 H24 F3 N5 O2



11/815,269

CM 2


CRN 76-05-1

CMF C2 H F3 O2



11/815,269


L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:131529 CAPLUS
DN 146:379920
TI Highly efficient ligands for dihydrofolate reductase from cryptosporidium
hominis and toxoplasma gondii inspired by structural analysis
AU Pelphrey, Phillip M.; Popov, Veljko M.; Joska, Tammy M.; Beierlein,
Jennifer M.; Bolstad, Erin S. D.; Fillingham, Yale A.; Wright, Dennis L.;
Anderson, Amy C.
CS Department of Chemistry, Dartmouth College, Hanover, NH, 03755, USA
SO Journal of Medicinal Chemistry (2007), 50(5), 940-950
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 146:379920
IT 928618-11-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
or reagent)
(preparation and dihydrofolate reductase inhibitory activity of
(arylethynyl)pyrimidines and (arylpropargyl)pyrimidines using
Sonogashira cross-coupling of iodopyrimidines with arylalkynes as key
step)
RN 928618-11-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-[2-(3,4,5-trimethoxyphenyl)ethynyl]- (CA INDEX
NAME)




RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

11/815,269

L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:66001 CAPLUS
DN 146:308393
TI Towards in silico lead optimization: scores from ensembles of
protein/ligand conformations reliably correlate with biological activity
AU Popov, Veljko M.; Yee, W. Atom; Anderson, Amy C.
CS Department of Chemistry, Dartmouth College, Hanover, NH, 03755, USA
SO Proteins: Structure, Function, and Bioinformatics (2007), 66(2), 375-387
CODEN: PSFBAF
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 928618-10-4 928618-11-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(scores from ensembles of protein/ligand conformations reliably
correlate with biol. activity)
RN 928618-10-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-[2-(2,3,4-trimethoxyphenyl)ethynyl]- (CA INDEX
NAME)




RN 928618-11-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-[2-(3,4,5-trimethoxyphenyl)ethynyl]- (CA INDEX
NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:60301 CAPLUS
 DN 146:243246
 TI 4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships
 of non-nucleoside adenosine kinase inhibitors
 AU Matulenko, Mark A.; Paight, Ernest S.; Frey, Robin R.; Gomtsyan, Arthur;
 DiDomenico, Stanley; Jiang, Meiqun; Lee, Chih-Hung; Stewart, Andrew O.;
 Yu, Haixia; Kohlhaas, Kathy L.; Alexander, Karen M.; McGaraughty, Steve;
 Mikusa, Joseph; Marsh, Kennan C.; Muchmore, Steven W.; Jakob, Clarissa L.;
 Kowaluk, Elizabeth A.; Jarvis, Michael F.; Bhagwat, Shripad S.
 CS Global Pharmaceutical Research, Neuroscience Research, Abbott
 Laboratories, Abbott Park, IL, 60064, USA
 SO Bioorganic & Medicinal Chemistry (2007), 15(4), 1586-1605
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 146:243246
 IT 926009-58-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (structure-activity relationships of non-nucleoside adenosine kinase
 inhibitors of aminoarylethynylpyrimidines)
 RN 926009-58-7 CAPLUS
 CN 4-Pyrimidinamine, 6-[4-(dimethylamino)phenyl]-5-[2-[4-
 (dimethylamino)phenyl]ethynyl]- (CA INDEX NAME)



RE.CNT 123 THERE ARE 123 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:33316 CAPLUS

DN 146:142672

TI Preparation of 2,4-diaminopyrimidines as aurora-b kinase inhibitors for the treatment of abnormal cell proliferation

IN Zahn, Stephan Karl; Boehmelt, Guido; Mantoulidis, Andreas; Reiser, Ulrich; Treu, Matthias; Guertler, Ulrich; Schoop, Andreas; Solca, Flavio; Tontsch-Grunt, Ulrike; Brueckner, Ralph; Reither, Charlotte; Herfurth, Lars; Kraemer, Oliver; Stadtmueller, Heinz; Engelhardt, Harald

PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG

SO PCT Int. Appl., 109pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007003596	A1	20070111	WO 2006-EP63736	20060630
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20070032514	A1	20070208	US 2006-475468	20060627
	AU 2006264958	A1	20070111	AU 2006-264958	20060630
	CA 2613664	A1	20070111	CA 2006-2613664	20060630
	EP 1902037	A1	20080326	EP 2006-763989	20060630
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	NO 2007006059	A	20080130	NO 2007-6059	20071126
	IN 2007DN09112	A	20080104	IN 2007-DN9112	20071127
	MX 200715992	A	20080307	MX 2007-15992	20071214
	CN 101213179	A	20080702	CN 2006-80024086	20071229
	KR 2008031362	A	20080408	KR 2008-702717	20080131
PRAI	EP 2005-106007	A	20050701		
	WO 2006-EP63736	W	20060630		

OS MARPAT 146:142672

IT 919116-23-7P 919116-25-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaminopyrimidines as aurora inhibitors for the treatment of abnormal cell proliferation)

RN 919116-23-7 CAPLUS

CN Cyclopentanecarboxamide, 2-[[5-(2-cyclopropylethynyl)-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 919116-25-9 CAPLUS

CN Benzamide, 4-[[4-[[[(1R,2S)-2-(aminocarbonyl)cyclopentyl]amino]-5-(2-phenylethynyl)-2-pyrimidinyl]amino]-N-(1-methyl-4-piperidinyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1356771 CAPLUS
 DN 146:100715
 TI Preparation of pyrimidine derivatives for the treatment of gaba b mediated nervous system disorders
 IN Floersheim, Philipp; Froestl, Wolfgang; Guery, Sebastien; Kaupmann, Klemens; Koller, Manuel
 PA Novartis AG, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 114pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006136442	A1	20061228	WO 2006-EP6083	20060623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006261122	A1	20061228	AU 2006-261122	20060623
	CA 2610742	A1	20061228	CA 2006-2610742	20060623
	EP 1896428	A1	20080312	EP 2006-762168	20060623
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007DN09085	A	20080104	IN 2007-DN9085	20071126
	CN 101193868	A	20080604	CN 2006-80020794	20071211
	MX 200716395	A	20080307	MX 2007-16395	20071218
	KR 2008017382	A	20080226	KR 2007-729918	20071221
PRAI	GB 2005-12844	A	20050623		
	WO 2006-EP6083	W	20060623		
OS	MARPAT 146:100715				
IT	917896-34-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine derivs. for the treatment of gaba b mediated nervous system disorders)				
RN	917896-34-5 CAPLUS				
CN	4-Pyrimidinamine, N-cyclopentyl-2-methyl-5-[2-[4-(trifluoromethyl)phenyl]ethynyl]- (CA INDEX NAME)				



11/815,269

ALL CITATIONS AVAILABLE IN THE RE FORMAT

11/815,269

L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1065980 CAPLUS
 DN 145:419166
 TI Preparation of pyrimidine derivatives as tyrosine kinase inhibitors
 IN Shiota, Takeshi; Suzuki, Naoyuki; Murashi, Takami
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 117pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006106721	A1	20061012	WO 2006-JP306445	20060329
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI JP 2005-97361 A 20050330

OS MARPAT 145:419166


IT 912353-86-7P 912353-87-8P 912353-88-9P
 912353-89-0P 912353-90-3P 912353-91-4P
 912353-95-8P 912353-96-9P 912353-97-0P
 912353-98-1P 912353-99-2P 912354-00-8P
 912354-01-9P 912354-07-5P 912354-09-7P
 912354-11-1P 912354-13-3P 912354-14-4P
 912354-16-6P 912354-18-8P 912354-20-2P
 912354-21-3P 912354-22-4P 912354-23-5P
 912354-25-7P 912354-26-8P 912354-27-9P
 912354-28-0P 912354-30-4P 912354-32-6P
 912354-34-8P 912354-91-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as tyrosine kinase inhibitors for treatment of cancer)

RN 912353-86-7 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-(4-morpholinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)



11/815,269


RN 912353-87-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[3-(4-morpholinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)




RN 912353-88-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-[(1-methylethyl)amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)




RN 912353-89-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-furanyl]ethynyl]- (CA INDEX NAME)




RN 912353-90-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 912353-91-4 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912353-95-8 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-thiazolyl]ethynyl]- (CA INDEX NAME)

11/815,269




RN 912353-96-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(1-pyrrolidinylmethyl)-2-furanyl]ethynyl]- (CA INDEX NAME)




RN 912353-97-0 CAPLUS


CN 3-Pyrrolidinol, 1-[[4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)



RN 912353-98-1 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-
[[3-methoxypropyl]amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)

RN 912353-99-2 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-
[[2-methoxyethyl]amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)


RN 912354-00-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-
[(dimethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-01-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[3-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)




RN 912354-07-5 CAPLUS

CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 912354-09-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(cyclopropylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-11-1 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-thienyl]ethynyl]- (CA INDEX NAME)




RN 912354-13-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(1-pyrrolidinylmethyl)-2-thienyl]ethynyl]- (CA INDEX NAME)




RN 912354-14-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-(dimethylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-16-6 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(methoxymethylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-18-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]-, O-methyloxime (CA INDEX NAME)




RN 912354-20-2 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-(1-pyrrolidinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)




RN 912354-21-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-[(1-methylethyl)amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)




RN 912354-22-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-(dimethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-23-5 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)




RN 912354-25-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(ethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-26-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-[[1-methylethyl]amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-27-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-28-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-(4-morpholinylmethyl)phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-30-4 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-32-6 CAPLUS


11/815,269

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(dimethylamino)methyl]-3-fluorophenyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 912354-34-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(ethylamino)methyl]-3-fluorophenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-91-7 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-[(1-methylethyl)amino]methyl]-3-furanyl]ethynyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:795559 CAPLUS
 DN 145:211065
 TI Preparation of pyrimidine derivatives and their use as Tie2 receptor
 tyrosine kinase inhibitors
 IN Jones, Clifford David; Luke, Richard William Arthur; Mccoull, William
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 106pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006082371	A1	20060810	WO 2006-GB272	20060127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1846399	A1	20071024	EP 2006-701130	20060127
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008528662	T	20080731	JP 2007-553682	20060127
	IN 2007DN05605	A	20070817	IN 2007-DN5605	20070719
	US 20080146599	A1	20080619	US 2007-815269	20070801
	CN 101151261	A	20080326	CN 2006-80010319	20070928
PRAI	GB 2005-1985	A	20050201		
	GB 2005-2543	A	20050208		
	GB 2005-12613	A	20050621		
	WO 2006-GB272	W	20060127		
OS	CASREACT 145:211065; MARPAT 145:211065				
IT	905277-19-2P 905277-20-5P 905277-21-6P 905277-22-7P 905277-23-8P 905277-24-9P 905277-25-0P 905277-26-1P 905277-28-3P 905277-29-4P 905277-30-7P 905277-31-8P 905277-32-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)				
RN	905277-19-2 CAPLUS				
CN	Benzenesulfonamide, 2-chloro-N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)				




RN 905277-20-5 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 905277-21-6 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 905277-22-7 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-fluoro- (CA INDEX NAME)



RN 905277-23-8 CAPLUS


CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



11/815,269


RN 905277-24-9 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2,5-difluoro- (CA INDEX NAME)




RN 905277-25-0 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-1-methyl- (CA INDEX NAME)




RN 905277-26-1 CAPLUS

CN 2-Thiophenesulfonamide, 5-chloro-N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 905277-28-3 CAPLUS

CN 4-Isoxazolesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3,5-dimethyl- (CA INDEX NAME)




RN 905277-29-4 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 905277-30-7 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-methoxy- (CA INDEX NAME)



RN 905277-31-8 CAPLUS


CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-fluoro- (CA INDEX NAME)




RN 905277-32-9 CAPLUS

CN Benzenesulfonamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-

fluoro- (CA INDEX NAME)




IT 857287-03-7P, 5-[(3-Aminophenyl)ethynyl]pyrimidine-4,6-diamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine
 kinase inhibitors)
 RN 857287-03-7 CAPLUS
 CN 4,6-Pyrimidinediamine, 5-[2-(3-aminophenyl)ethynyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:790854 CAPLUS
 DN 145:230644
 TI Preparation of pyrimidine derivatives and their use as Tie2 receptor
 tyrosine kinase inhibitors
 IN Jones, Clifford David; Luke, Richard William Arthur; Mccoull, William
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 168pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006082373	A1	20060810	WO 2006-GB284	20060127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1863805	A1	20071212	EP 2006-701245	20060127
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008528663	T	20080731	JP 2007-553683	20060127
	IN 2007DN05604	A	20070817	IN 2007-DN5604	20070719
	CN 101137652	A	20080305	CN 2006-80007855	20070911
PRAI	GB 2005-1984	A	20050201		
	GB 2005-2417	A	20050205		
	GB 2005-12614	A	20050621		
	WO 2006-GB284	W	20060127		
OS	MARPAT 145:230644				
IT	905439-67-0P	905439-70-5P	905439-72-7P		
	905439-73-8P	905439-74-9P	905439-75-0P		
	905439-76-1P	905439-77-2P	905439-79-4P		
	905439-82-9P	905439-84-1P	905439-85-2P		
	905439-86-3P	905439-87-4P	905439-89-6P		
	905439-92-1P	905439-94-3P	905439-97-6P		
	905439-98-7P	905440-01-9P	905440-03-1P		
	905440-05-3P	905440-07-5P	905440-09-7P		
	905440-12-2P	905440-15-5P	905440-17-7P		
	905440-20-2P	905440-23-5P			
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)				
RN	905439-67-0	CAPLUS			
CN	Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1,4-dioxan-2-ylmethyl)-	(CA INDEX NAME)			




RN 905439-70-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(5-methyl-2-pyrazinyl)methyl]- (CA INDEX NAME)




RN 905439-72-7 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 905439-73-8 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 905439-74-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(1H-pyrazol-1-yl)propyl]- (CA INDEX NAME)




RN 905439-75-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 905439-76-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 905439-77-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(4-methyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 905439-79-4 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(4-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 905439-82-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 905439-84-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 905439-85-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[[2-(4-morpholinyl)phenyl]methyl]- (CA INDEX NAME)




RN 905439-86-3 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)




RN 905439-87-4 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 905439-89-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(3-pyridazinyloxy)ethyl]- (CA INDEX NAME)




RN 905439-92-1 CAPLUS

CN Urea, N-(cyclopropylmethyl)-N'-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)



RN 905439-94-3 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(4-pyrimidinyl)ethyl]- (CA INDEX NAME)



RN 905439-97-6 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)

11/815,269




RN 905439-98-7 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]- (CA INDEX NAME)




RN 905440-01-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[[4-(4-morpholinyl)-5-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 905440-03-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 905440-05-3 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 905440-07-5 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

11/815,269




RN 905440-09-7 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(2-pyridinylamino)ethyl]- (CA INDEX NAME)



RN 905440-12-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



11/815,269


RN 905440-15-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(1-piperidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 905440-14-4

CMF C20 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 905440-17-7 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)



RN 905440-20-2 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]- (CA INDEX NAME)



11/815,269

RN 905440-23-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(phenylmethyl)-
(CA INDEX NAME)



IT 857287-03-7P, 5-[(3-Aminophenyl)ethynyl]pyrimidine-4,6-diamine


857287-13-9P, Phenyl[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)


RN 857287-03-7 CAPLUS

CN 4,6-Pyrimidinediamine, 5-[2-(3-aminophenyl)ethynyl]- (CA INDEX NAME)




RN 857287-13-9 CAPLUS

CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:713136 CAPLUS
 DN 145:335838
 TI Synthesis of N1-unsubstituted 5-alkynyl-cytosine and derivatives thereof
 AU Hudson, Robert H. E.; Dambenieks, Andrew K.
 CS Department of Chemistry, The University of Western Ontario, London, ON,
 N6A 5B7, Can.
 SO Heterocycles (2006), 68(7), 1325-1328
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 145:335838
 IT 896450-72-9P 896450-73-0P 909712-57-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of N1-unsubstituted 5-alkynyl-cytosine via Sonogashira
 coupling of 5-iodocytosine with terminal alkynes and cross-coupling and
 cyclization reactions)
 RN 896450-72-9 CAPLUS
 CN 2(1H)-Pyrimidinone, 6-amino-5-(2-phenylethynyl)- (CA INDEX NAME)



RN 896450-73-0 CAPLUS
 CN 2(1H)-Pyrimidinone, 6-amino-5-[2-(4-methoxyphenyl)ethynyl]- (CA INDEX NAME)




RN 909712-57-8 CAPLUS
 CN 2(1H)-Pyrimidinone, 6-amino-5-[2-(4-nitrophenyl)ethynyl]- (CA INDEX NAME)




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:274296 CAPLUS
 DN 144:488615
 TI Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors
 AU Waterson, Alex G.; Stevens, Kirk L.; Reno, Michael J.; Zhang, Yue-Mei;
 Boros, Eric E.; Bouvier, Frederic; Rastagar, Abdullah; Uehling, David E.;
 Dickerson, Scott H.; Reep, Bryan; McDonald, Ochterloney B.; Wood, Edgar R.;
 Rusnak, David W.; Alligood, Krystal J.; Rudolph, Sharon K.
 CS GlaxoSmithKline, Research Triangle Park, NC, 27709-3398, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(9), 2419-2422
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:488615
 IT 845657-38-7P 845657-48-9P 845657-82-1P
 845658-03-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
 or reagent)
 (preparation of alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors)
 RN 845657-38-7 CAPLUS
 CN 4-Pyrimidinamine, 5-[2-(3-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-
 fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-48-9 CAPLUS
 CN 4-Pyrimidinamine, 5-[2-(4-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-
 fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845657-82-1 CAPLUS
 CN 2-Pyridinemethanol, 6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]a
 mino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845658-03-9 CAPLUS

CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




IT 845657-23-0P 845657-32-1P 845657-39-8P
 845657-45-6P 845657-47-8P 845657-53-6P
 845657-57-0P 845657-58-1P 845657-74-1P
 845658-08-4P 845658-12-0P 845658-25-5P
 887147-46-8P 887147-47-9P 887147-48-0P
 887147-49-1P 887147-50-4P 887147-51-5P
 887147-52-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors)


RN 845657-23-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-pyridinyl)ethynyl]- (CA INDEX NAME)




RN 845657-32-1 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyrimidinyl)ethynyl]- (CA INDEX NAME)




RN 845657-39-8 CAPLUS

CN Acetamide, N-[3-[2-[4-[(3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-45-6 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-(2-phenylethynyl)- (CA INDEX NAME)




RN 845657-47-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyridinyl)ethynyl]- (CA INDEX NAME)




RN 845657-53-6 CAPLUS

CN Acetamide, N-[3-[2-[4-[(3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)




RN 845657-57-0 CAPLUS

CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-58-1 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-74-1 CAPLUS

CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]- (CA INDEX NAME)




RN 845658-08-4 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 845658-12-0 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl- (CA INDEX NAME)




RN 845658-25-5 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(2-amino-4-pyrimidinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 887147-46-8 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(2-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 887147-47-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 887147-48-0 CAPLUS

CN Methanesulfonamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 887147-49-1 CAPLUS

CN Benzamide, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-N-methyl- (CA INDEX NAME)



RN 887147-50-4 CAPLUS


CN Propanamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-3-(methylsulfonyl)- (CA INDEX NAME)



RN 887147-51-5 CAPLUS


CN Pentanoic acid, 5-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]amino]-5-oxo-, methyl ester (CA INDEX NAME)

11/815,269



RN 987147-52-6 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1H-pyrazol-3-yl)ethynyl]- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:104519 CAPLUS
 DN 144:171009
 TI Preparation of pyrimidine derivatives as selective inhibitors of protein
 kinase C α with therapeutic uses
 IN Barbosa, Antonio J. M.; Brunette, Steven Richard; Hickey, Eugene Richard;
 Kim, Jin Mi; Lawlor, Michael David; Lemieux, Rene Marc; Mckibben, Bryan;
 Tschantz, Matt Aaron; Yu, Hui
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SO U.S. Pat. Appl. Publ., 156 pp.
 CODEN: USXXCO


DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060025433	A1	20060202	US 2005-175476	20050706
	CA 2571937	A1	20060209	CA 2005-2571937	20050706
	WO 2006014482	A1	20060209	WO 2005-US23969	20050706
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	EP 1765791	A1	20070328	EP 2005-769520	20050706
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008505910	T	20080228	JP 2007-520469	20050706
PRAI	US 2004-586289P	P	20040708		
	WO 2005-US23969	W	20050706		
OS	MARPAT 144:171009				
IT	874823-40-2P, N'-[(trans-4-Aminocyclohexyl)methyl]-5-(phenylethynyl)-N-[2-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine				
	874823-42-4P, N'-[(trans-4-Aminocyclohexyl)methyl]-N-[2-(trifluoromethoxy)benzyl]-5-[[3-(trifluoromethyl)phenyl]ethynyl]pyrimidine-2,4-diamine				
	874823-44-6P, N'-[(trans-4-Aminocyclohexyl)methyl]-N-[2-(trifluoromethoxy)benzyl]-5-[[2-(trifluoromethyl)phenyl]ethynyl]pyrimidine-2,4-diamine				
	874823-45-7P, N'-[(trans-4-Aminocyclohexyl)methyl]-5-[[3-methylphenyl]ethynyl]-N-[2-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine				
	874823-46-8P, N'-[(trans-4-Aminocyclohexyl)methyl]-5-[[4-methylphenyl]ethynyl]-N-[2-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of pyrimidine derivs. as selective inhibitors of protein kinase C α with therapeutic uses)				
RN	874823-40-2 CAPLUS				
CN	2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-5-(2-phenylethynyl)-N2-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)				

11/815,269


Relative stereochemistry.



RN 874823-42-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-N2-[[2-(trifluoromethoxy)phenyl)methyl]-5-[2-[3-(trifluoromethyl)phenyl]ethynyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 874823-43-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-5-[2-(2-fluorophenyl)ethynyl]-N2-[[2-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 874823-44-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-N2-[[2-(trifluoromethoxy)phenyl]methyl]-5-[2-[2-(trifluoromethyl)phenyl]ethynyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 874823-45-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-5-[2-(3-methylphenyl)ethynyl]-N2-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 874823-46-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(trans-4-aminocyclohexyl)methyl]-5-[2-(4-methylphenyl)ethynyl]-N2-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)


11/815,269

NAME)


Relative stereochemistry.



L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1323349 CAPLUS
 DN 145:98853
 TI New fluorescent nucleobases derived from 5-alkynylpyrimidines
 AU Hudson, Robert H. E.; Dambenieks, Andrew K.; Moszynski, Joanne M.
 CS Department of Chemistry, The Univ. of Western Ontario, London, ON, N6A
 1X8, Can.
 SO Proceedings of SPIE-The International Society for Optical Engineering
 (2005), 5969 (Photonic Applications in Biosensing and Imaging),
 59690J/1-59690J/10
 CODEN: PSISDG; ISSN: 0277-786X
 PB SPIE-The International Society for Optical Engineering
 DT Journal
 LA English
 IT 896450-72-9P 896450-73-0P
 RL: ARG (Analytical reagent use); PRP (Properties); SPN (Synthetic
 preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
 (synthesis of fluorescent nucleobases derived from 5-alkynylpyrimidines
 for fluorometry of oligonucleotides)
 RN 896450-72-9 CAPLUS
 CN 2(1H)-Pyrimidinone, 6-amino-5-(2-phenylethynyl)- (CA INDEX NAME)




RN 896450-73-0 CAPLUS
 CN 2(1H)-Pyrimidinone, 6-amino-5-[2-(4-methoxyphenyl)ethynyl]- (CA INDEX
 NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:588667 CAPLUS
 DN 143:115556
 TI Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2
 receptor tyrosine kinases
 IN Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005060969	A1	20050707	WO 2004-GB5332	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1737462	A1	20070103	EP 2004-806134	20041220
	EP 1737462	B1	20080730		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1917880	A	20070221	CN 2004-80041936	20041220
	JP 2007517006	T	20070628	JP 2006-546305	20041220
	AT 402705	T	20080815	AT 2004-806134	20041220
	US 20080027076	A1	20080131	US 2006-596740	20060622
	IN 2006MN00847	A	20070420	IN 2006-MN847	20060717
PRAI	GB 2003-30001	A	20031224		
	GB 2004-16850	A	20040729		
	WO 2004-GB5332	W	20041220		
OS	CASREACT 143:115556; MARPAT 143:115556				
IT	857287-13-9P, Phenyl [3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-53-7P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)				
RN	857287-13-9 CAPLUS				
CN	Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)				



RN 857287-53-7 CAPLUS

Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[4-[(2-(4-morpholinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



IT 857287-02-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857287-04-8P, 2-Phenyl-N-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857287-05-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)urea 857287-06-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]urea 857287-07-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857287-08-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]urea 857287-09-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea 857287-10-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857287-11-7P, Phenyl [4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-14-0P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-15-1P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-16-2P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-17-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-18-4P, N-[3-[[[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-19-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-20-8P, N-[3-[[[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-21-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-22-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-23-1P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-24-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-25-3P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 857287-26-4P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(morpholin-4-yl)phenyl]urea 857287-27-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-methylpiperidin-4-yl)urea 857287-28-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-propylpiperidin-4-yl)urea 857287-29-7P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857287-30-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857287-31-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide


857287-32-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857287-35-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857287-36-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-37-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(5-tert-butylisoxazol-3-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-39-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-40-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2-hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-41-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-42-4P, N-[3-[[4-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-43-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-(pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-44-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2,4-dimethoxybenzyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-45-7P, N-[3-[[4-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-46-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-47-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[4-(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-48-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[N-(2-(dimethylamino)ethyl)methylamino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-49-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(piperidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-50-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-51-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-52-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(3-(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-57-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857287-02-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857287-04-8 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-05-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 857287-06-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 857287-07-1 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 857287-08-2 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)

11/815,269




RN 857287-09-3 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857287-10-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 857287-11-7 CAPLUS

CN Carbamic acid, [4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-14-0 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857287-15-1 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)



RN 857287-16-2 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-17-3 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-


11/815,269

(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-18-4 CAPLUS

CN Acetamide, N-[3-[[[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 857287-19-5 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)



RN 857287-20-8 CAPLUS


CN Acetamide, N-[3-[[[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

11/815,269




RN 857287-21-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-22-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 857287-23-1 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)



11/815,269


RN 857287-24-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-25-3 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)




RN 857287-26-4 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-(4-morpholinyl)phenyl)- (CA INDEX NAME)




RN 857287-27-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-4-piperidyl)- (CA INDEX NAME)




RN 857287-28-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-propyl-4-piperidyl)- (CA INDEX NAME)




RN 857287-29-7 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857287-30-0 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-31-1 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 857287-32-2 CAPLUS


CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)



11/815,269


RN 857287-35-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-36-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-37-7 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-38-8 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857287-39-9 CAPLUS

CN Urea, N-[3-[2-[4-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-40-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(2-hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-41-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(2-(4-morpholinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-42-4 CAPLUS

CN Urea, N-[3-[2-[4-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(1,1-dimethylethyl)-3-isoxazolyl- (CA INDEX NAME)




RN 857287-43-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857287-44-6 CAPLUS

CN Urea, N-[3-[2-[4-[(2,4-dimethoxyphenyl)methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(1,1-dimethylethyl)-3-isoxazolyl- (CA INDEX NAME)




RN 857287-45-7 CAPLUS

CN Urea, N-[3-[2-[4-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-46-8 CAPLUS

CN Urea, N-[3-[2-[4-[(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



RN 857287-47-9 CAPLUS


CN Urea, N-[3-[2-[4-[(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



RN 857287-48-0 CAPLUS


CN Urea, N-[3-[2-[4-[(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)

INDEX NAME)




RN 857287-49-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-piperidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-50-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-51-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-52-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-57-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)- (CA INDEX NAME)




IT 857287-12-8, 5-[(4-Aminophenyl)ethynyl]pyrimidine-4,6-diamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857287-12-8 CAPLUS

CN 4,6-Pyrimidinediamine, 5-[2-(4-aminophenyl)ethynyl]- (CA INDEX NAME)



IT 857287-03-7P, 5-[(3-Aminophenyl)ethynyl]pyrimidine-4,6-diamine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857287-03-7 CAPLUS

CN 4,6-Pyrimidinediamine, 5-[2-(3-aminophenyl)ethynyl]- (CA INDEX NAME)


11/815,269



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:158661 CAPLUS
 DN 142:240460
 TI Preparation of pyrimidine derivatives as ErbB kinase inhibitors
 IN Reno, Michael John; Stevens, Kirk Lawrence; Waterson, Alex Gregory; Zhang, Yuemei
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016914	A1	20050224	WO 2004-US26251	20040811
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1654251	A1	20060510	EP 2004-781004	20040811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007502298	T	20070208	JP 2006-523388	20040811
	US 20060205740	A1	20060914	US 2006-568052	20060210
PRAI	US 2003-495180P	P	20030814		
	WO 2004-US26251	W	20040811		
OS	CASREACT 142:240460; MARPAT 142:240460				
IT	845657-38-7P, 5-[(3-Aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrimidin-4-amine 845657-39-8P, N-[3-[[4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-51-4P, tert-Butyl [[3-[[4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethynyl]phenyl]methyl]carbamate 845657-55-8P, 5-[[4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethynyl]-2-furaldehyde 845657-72-9P, 5-[(6-Amino-2-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methyl]oxy]phenyl]-4-pyrimidinamine 845657-82-1P, [6-[[4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]anilino)-5-pyrimidinyl]ethynyl]-2-pyridinyl]methanol 845658-03-9P, 5-[[6-(Aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-4-pyrimidinamine 845658-04-0P, 5-[[6-(Aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-4-pyrimidinamine bis(fluoroacetate) 845658-22-2P, 4-Amino-2-[[4-[(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]pyrimidin-5-yl]ethynyl]pyrimidine-5-carbonitrile RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyrimidines as ERB kinase inhibitors)				
RN	845657-38-7 CAPLUS				
CN	4-Pyrimidinamine, 5-[2-(3-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)				




RN 845657-39-8 CAPLUS

CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-51-4 CAPLUS

CN Carbamic acid, [[3-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845657-55-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-72-9 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(6-amino-2-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-82-1 CAPLUS


CN 2-Pyridinemethanol, 6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845658-03-9 CAPLUS

CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)

11/815,269




RN 845658-04-0 CAPLUS
 CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 845658-03-9

CMF C25 H19 Cl F N5 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 845658-22-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-amino-2-[2-[4-[[3-chloro-4-[(4-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



IT 845657-23-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-
 [(pyridin-3-yl)ethynyl]pyrimidin-4-amine 845657-24-1P,
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1-methyl-1H-imidazol-5-
 yl)ethynyl]pyrimidin-4-amine 845657-26-3P, N-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]-5-[(1H-pyrazol-4-yl)ethynyl]pyrimidin-4-amine
 845657-27-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-
 [(pyrimidin-5-yl)ethynyl]pyrimidin-4-amine 845657-28-5P,
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1,3-thiazol-2-
 yl)ethynyl]pyrimidin-4-amine 845657-30-9P, N-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]-5-[(thien-3-yl)ethynyl]pyrimidin-4-amine
 845657-31-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(2-
 morpholin-4-yl)pyrimidin-4-yl]ethynyl]pyrimidin-4-amine
 845657-32-1P, N-[3-Chloro-4-[(3-fluorophenyl)methyl]oxy]phenyl]-5-
 [(2-pyrimidinyl)ethynyl]-4-pyrimidinamine 845657-34-3P,
 5-[(6-Amino-3-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-
 fluorophenyl)methyl]oxy]phenyl]-4-pyrimidinamine 845657-35-4P,
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(3-
 fluorophenyl)ethynyl]pyrimidin-4-amine 845657-36-5P,
 4-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-
 yl]ethynyl]phenol 845657-37-6P, N-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]-5-[(6-methoxy-pyridin-2-yl)ethynyl]pyrimidin-4-
 amine 845657-40-1P, N-[3-[[4-[[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]ethanethioamid
 e 845657-41-2P, 2-[[4-[[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzonitrile
 845657-42-3P, 3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino
]pyrimidin-5-yl]ethynyl]benzonitrile 845657-43-4P,
 3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-
 yl]ethynyl]benzaldehyde 845657-45-6P, N-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]-5-(phenylethynyl)pyrimidin-4-ylamine
 845657-47-8P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-
 [(pyridin-2-yl)ethynyl]pyrimidin-4-amine 845657-48-9P,
 5-[[4-Aminophenyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrim
 idin-4-amine 845657-49-0P, N-[3-[[4-[[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-3-
 (methylthio)propanamide 845657-50-3P, N-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]-5-[[1-[(4-methylphenyl)sulfonyl]-1H-indol-6-
 yl]ethynyl]pyrimidin-4-amine 845657-52-5P, N-[3-[[4-[[3-Chloro-4-
 [(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]guanidine
 845657-53-6P, N-[3-[[4-[[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzyl]acetamide
 845657-54-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[3-
 [[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]pyrimidin-4-amine
 845657-56-9P, 3-[[5-[[4-[[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-2-
 furyl]methyl]amino]propanenitrile 845657-57-0P,

[5-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-2-furyl]methanol 845657-58-1P, [4-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-1,3-thiazol-2-yl]methanol 845657-59-2P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[1,2,3,4-tetrahydroisoquinolin-7-yl]ethynyl]pyrimidin-4-amine 845657-61-6P, 2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzaldehyde 845657-62-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]ethynyl]pyrimidin-4-amine 845657-63-8P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-2-(2-methoxyethoxy)acetamide 845657-64-9P, N-[3-[[4-[[2-Benzyl-1H-benzimidazol-5-yl]amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-65-0P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-β-alaninamide 845657-66-1P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-2-(methylsulfonyl)acetamide 845657-67-2P, N-[3-[[4-[[4-Benzylphenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-68-3P, N-[3-[[4-[[4-Phenoxyphenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-69-4P, N-[3-[[4-[[1-Benzyl-1H-indazol-5-yl]amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-70-7P, 1-Benzyl-N-[5-(phenylethynyl)pyrimidin-4-yl]-1H-indol-5-amine 845657-74-1P, N-[6-[2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]pyrimidin-5-yl]ethynyl]pyridin-2-yl]acetamide 845657-76-3P, 2-Chloro-N-[6-[[4-[[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2-difluoroacetamide 845657-77-4P, N-[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-4-(dimethylamino)butanamide 845657-78-5P, Methyl 4-[[6-[[4-[[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]amino]-4-oxobutanoate 845657-80-9P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[2-(methylsulfonyl)ethyl]amino]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-84-3P, 2-[[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl](methyl)amino]ethanol 845657-85-4P, 3-[[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]propanenitrile 845657-86-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[2-(4-morpholinyl)ethyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-88-7P, N-[2-[[6-[[2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]ethyl]acetamide 845657-90-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-92-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[methylamino]methyl]pyridin-2-yl]ethynyl]-4-pyrimidinamine 845657-94-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-(methoxymethyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-95-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[2-(methylsulfonyl)-4-pyrimidinyl]ethynyl]-4-pyrimidinamine 845657-97-8P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[dimethylamino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-98-9P, N-Benzyl-N-[6-[[4-[[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amine 845658-00-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[2-methoxyethyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845658-05-1P, 1-[[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-(2-cyanoethyl)urea 845658-07-3P, 3-[[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-


5-pyrimidinyl]ethynyl]-2-pyridinyl)methyl]-1-(2-hydroxyethyl)-1-methylurea
 845658-08-4P, 1-[6-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-
 5-pyrimidinyl]ethynyl]-2-pyridinyl)methyl]-3-[2-(methylsulfonyl)ethyl]urea
 845658-10-8P, 1-[6-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-
 5-pyrimidinyl]ethynyl]-2-pyridinyl)methyl]-3-[2-(4-morpholinyl)ethyl]urea
 845658-12-0P, 1-[6-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-
 5-pyrimidinyl]ethynyl]-2-pyridinyl)methyl]-3-methylurea
 845658-14-2P, 1-[6-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-
 5-pyrimidinyl]ethynyl]-2-pyridinyl)methyl]-3-(2-methoxyethyl)urea
 845658-15-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[6-[1-(
 piperidinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
 845658-16-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[6-[1-(4-
 methyl-1-piperazinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
 845658-18-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[6-[1-(4-
 morpholinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
 845658-19-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[6-[1-(1-
 pyrrolidinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
 845658-20-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[6-[1-(1-
 piperazinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
 845658-24-4P, 2-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino
]pyrimidin-5-yl]ethynyl]-4-[2-(methylsulfonyl)ethyl]amino]pyrimidine-5-
 carbonitrile 845658-25-5P, 4-[4-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]pyrimidin-2-amine
 845658-26-6P, N-[6-[4-[3-Chloro-4-[(3-
 fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]pyridin-2-yl]-2,2,2-
 trifluoroacetamide 845658-30-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrimidines as ErB kinase inhibitors)


RN 845657-23-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-
 pyridinyl)ethynyl]- (CA INDEX NAME)




RN 845657-24-1 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1-
 methyl-1H-imidazol-5-yl)ethynyl]- (CA INDEX NAME)




RN 845657-26-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1H-pyrazol-4-yl)ethynyl]- (CA INDEX NAME)




RN 845657-27-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(5-pyrimidinyl)ethynyl]- (CA INDEX NAME)




RN 845657-28-5 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-thiazolyl)ethynyl]- (CA INDEX NAME)




RN 845657-30-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-thienyl)ethynyl]- (CA INDEX NAME)




RN 845657-31-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[2-(4-morpholinyl)-4-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-32-1 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyrimidinyl)ethynyl]- (CA INDEX NAME)




RN 845657-34-3 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(6-amino-3-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845657-35-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 845657-36-5 CAPLUS


CN Phenol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-37-6 CAPLUS


11/815,269

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(6-methoxy-2-pyridinyl)ethynyl]- (CA INDEX NAME)




RN 845657-40-1 CAPLUS

CN Ethanethioamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-41-2 CAPLUS

CN Benzonitrile, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-42-3 CAPLUS

CN Benzonitrile, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-43-4 CAPLUS

CN Benzaldehyde, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-45-6 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-(2-phenylethynyl)- (CA INDEX NAME)




RN 845657-47-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyridinyl)ethynyl]- (CA INDEX NAME)




RN 845657-48-9 CAPLUS

CN 4-Pyrimidinamine, 5-[2-(4-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 845657-49-0 CAPLUS

CN Propanamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-3-(methylthio)- (CA INDEX NAME)




RN 845657-50-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-[2-[4-[(3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-[2-[1-[(4-methylphenyl)sulfonyl]-1H-indol-6-yl]ethynyl]- (CA INDEX NAME)




RN 845657-52-5 CAPLUS

CN Guanidine, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-53-6 CAPLUS

CN Acetamide, N-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)




RN 845657-54-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)




RN 845657-56-9 CAPLUS

CN Propanenitrile, 3-[[[5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-furanyl]methyl]amino]- (CA INDEX NAME)




RN 845657-57-0 CAPLUS

CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-58-1 CAPLUS

CN 2-Thiazolemethanol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-59-2 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1,2,3,4-tetrahydro-7-isoquinolinyl)ethynyl]- (CA INDEX NAME)




RN 845657-61-6 CAPLUS

CN Benzaldehyde, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-62-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)




RN 845657-63-8 CAPLUS

CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)




RN 845657-64-9 CAPLUS

CN Acetamide, N-[3-[2-[4-[[2-(phenylmethyl)-1H-benzimidazol-6-yl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-65-0 CAPLUS

CN Propanamide, 3-amino-N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 845657-66-1 CAPLUS

CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-2-(methylsulfonyl)- (CA INDEX NAME)




RN 845657-67-2 CAPLUS

CN Acetamide, N-[3-[2-[4-[(phenylmethyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-68-3 CAPLUS


CN Acetamide, N-[3-[2-[4-[(4-phenoxyphenyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-69-4 CAPLUS


CN Acetamide, N-[3-[2-[4-[(1-(phenylmethyl)-1H-indazol-5-yl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

11/815,269




RN 845657-70-7 CAPLUS

CN 1H-Indol-5-amine, N-[5-(2-phenylethynyl)-4-pyrimidinyl]-1-(phenylmethyl)-
(CA INDEX NAME)




RN 845657-74-1 CAPLUS

CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-
5-pyrimidinyl]ethynyl]-2-pyridinyl]- (CA INDEX NAME)




RN 845657-76-3 CAPLUS

CN Acetamide, 2-chloro-N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2-
difluoro- (CA INDEX NAME)




RN 845657-77-4 CAPLUS

CN Butanamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 845657-78-5 CAPLUS

CN Butanoic acid, 4-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)




RN 845657-80-9 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[2-(methylsulfonyl)ethyl]amino]-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845657-84-3 CAPLUS

CN Ethanol, 2-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]methylamino]- (CA INDEX NAME)




RN 845657-85-4 CAPLUS

CN Propanenitrile, 3-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)




RN 845657-86-5 CAPLUS

CN 4-Morpholineethanamine, N-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 845657-92-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[(methylamino)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845657-94-5 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(methoxymethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845657-95-6 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[2-(methylthio)-4-pyrimidinyl]ethynyl]- (CA INDEX NAME)




RN 845657-97-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-
[(dimethylamino)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)

RN 845657-98-9 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-
[(phenylmethyl)amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)

RN 845658-00-6 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-
[(2-methoxyethyl)amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)


RN 845658-05-1 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-(2-cyanoethyl)- (CA INDEX NAME)




RN 845658-07-3 CAPLUS

CN Urea, N'-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)



RN 845658-08-4 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 845658-10-8 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-

11/815,269

pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(4-morpholinyl)ethyl]- (CA
INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 845658-12-0 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-
pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl- (CA INDEX NAME)




RN 845658-14-2 CAPLUS

CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)




RN 845658-15-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-piperidinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-16-4 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-18-6 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-

(4-morpholinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845658-19-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-pyrrolidinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845658-20-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-piperazinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)




RN 845658-24-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-4-[[2-(methylsulfonyl)ethyl]amino]- (CA INDEX NAME)




RN 845658-25-5 CAPLUS

CN 4-Pyrimidinamine, 5-[2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-2,2,2-trifluoroacetamide (CA INDEX NAME)




RN 845658-26-6 CAPLUS

CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 845658-30-2 CAPLUS


CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-thienyl)ethynyl]- (CA INDEX NAME)



IT 845658-58-4P, 5-[[3-(Aminomethyl)phenyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrimidin-4-amine 845658-77-7P;
 Di(tert-butyl)[6-[[4-[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl] methyl imidodicarbonate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrimidines as ErbB kinase inhibitors)

RN 845658-58-4 CAPLUS


CN 4-Pyrimidinamine, 5-[2-{3-(aminomethyl)phenyl}ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845658-77-7 CAPLUS

CN Imidodicarbonic acid, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)


11/815,269



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:984717 CAPLUS
 DN 142:190983
 TI KP544, a nerve growth factor amplifier: pharmacokinetics, safety, and efficacy in the rat
 AU Krenitsky, Thomas A.; Dillberger, John; Zotova, Elena; Arezzo, Joseph C.; Koprach, James B.; Mortazavi, Farzad; Gates, Timothy A.; Dunbar, Gary L.
 CS Krenitsky Pharmaceuticals Inc., Durham, NC, USA
 SO Drug Development Research (2004), 62(1), 60-70
 CODEN: DDREDK; ISSN: 0272-4391
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 IT 393856-87-6, KP 544
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nerve growth factor amplifier KP544 pharmacokinetics, safety, and efficacy in rat)
 RN 393856-87-6 CAPLUS
 CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



IT 393856-89-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nerve growth factor amplifier KP544 pharmacokinetics, safety, and efficacy in rat)
 RN 393856-89-8 CAPLUS
 CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

11/815,269




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

11/815,269

L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:984716 CAPLUS
DN 142:212157
TI KP544 amplifies the effects of nerve growth factor on cell differentiation
and is neuroprotective
AU Fyfe, James A.; Beauchamp, Lilia M.; Caggiano, Anthony O.; Price, Raymond
D.; Yamaji, Takayuki; Matsuoka, Nobuya; Krenitsky, Thomas A.
CS Krenitsky Pharmaceuticals Inc., Durham, NC, USA
SO Drug Development Research (2004), 62(1), 49-59
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 393856-87-6, KP 544
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL
(Biological study)
(KP544 amplifies the effects of nerve growth factor on cell
differentiation and is neuroprotective)
RN 393856-87-6 CAPLUS
CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-
pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:120856 CAPLUS
 DN 140:163889
 TI Preparation of condensed pyridines and pyrimidines as Tie2 receptor
 tyrosine kinase inhibitors and their anti-angiogenic effect
 IN Luke, Richard William Arthur; Jones, Clifford David; McCoull, William;
 Hayter, Barry Raymond
 PA AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SO PCT Int. Appl., 184 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013141	A1	20040212	WO 2003-GB3275	20030801
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494421	A1	20040212	CA 2003-2494421	20030801
	AU 2003246972	A1	20040223	AU 2003-246972	20030801
	EP 1537112	A1	20050608	EP 2003-766443	20030801
	EP 1537112	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013078	A	20050712	BR 2003-13078	20030801
	CN 1688579	A	20051026	CN 2003-823754	20030801
	JP 2005538118	T	20051215	JP 2004-525533	20030801
	AT 323702	T	20060515	AT 2003-766443	20030801
	NO 2005000418	A	20050428	NO 2005-418	20050125
	ZA 2005000863	A	20060222	ZA 2005-863	20050128
	MX 2005PA01389	A	20050428	MX 2005-PA1389	20050203
	US 20050256140	A1	20051117	US 2005-523401	20050203
	US 7427616	B2	20080923		
PRAI	GB 2002-18168	A	20020806		
	GB 2003-12356	A	20030530		
	WO 2003-GB3275	W	20030801		
OS	MARPAT 140:163889				
IT	655253-95-5P, 5-[(1-Methyl-4-phenyl-1H-imidazol-5-yl)ethynyl]pyrimidin-4-amine				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of condensed pyridines and pyrimidines as Tie2 receptor tyrosine kinase inhibitors)				
RN	655253-95-5 CAPLUS				
CN	4-Pyrimidinamine, 5-[2-(1-methyl-4-phenyl-1H-imidazol-5-yl)ethynyl]- (CA INDEX NAME)				

11/815,269



L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:90025 CAPLUS

DN 136:151172

TI Preparation of 5-(arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegenerative and other neurological disorders

IN Beauchamp, Lilia; Krenitsky, Thomas A.; Kelley, James L.

FA Krenitsky Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002008205	A1	20020131	WO 2001-US23088	20010720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2416442	A1	20020131	CA 2001-2416442	20010720
	AU 2001073574	A	20020205	AU 2001-73574	20010720
	EP 1303495	A1	20030423	EP 2001-952859	20010720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004504386	T	20040212	JP 2002-514111	20010720
	US 20040087789	A1	20040506	US 2003-333447	20030627
	US 7205297	B2	20070417		
PRAI	US 2000-220348P	P	20000724		
	WO 2001-US23088	W	20010720		
OS	MARPAT 136:151172				
IT	393856-66-1P, 2-Amino-5-(4-chlorophenylethynyl)-4-(4-oxocyclohexylamino)pyrimidine 393856-71-8P, 2-Amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-87-6P, 2-Amino-5-(4-chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine 393857-07-3P, 2-Disopropylaminomethyleneamino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(CNS agent; preparation of (arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegenerative and other neurological disorders)				
RN	393856-66-1 CAPLUS				
CN	Cyclohexanone, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)				


11/815,269



RN 393856-71-8 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-bromophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 393856-87-6 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 393857-07-3 CAPLUS

CN Methanimidamide, N'-[4-[(trans-4-hydroxycyclohexyl)amino]-5-(2-phenylethynyl)-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



IT 393855-73-7P, 4-(trans-4-Hydroxycyclohexylamino)-5-phenylethynylpyrimidine 393855-76-0P, 4-[2-(2-Hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine 393855-79-3P, 5-(4-Chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine 393855-81-7P, 2-Amino-5-(4-chlorophenylethynyl)-4-[2-(2-hydroxyethoxy)ethylamino]pyrimidine 393856-02-5P, 4-(2-Hydroxyethylamino)-5-phenylethynylpyrimidine 393856-04-7P, 2-Amino-4-(2-hydroxyethylamino)-5-phenylethynylpyrimidine 393856-07-0P, 2-Amino-4-(4-hydroxyanilino)-5-phenylethynylpyrimidine 393856-10-5P, 2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-n-pentylphenylethynyl)pyrimidine 393856-13-8P, 2-Acetamido-4-(4-trans-acetoxycyclohexylamino)-5-(4-chlorophenylethynyl)pyrimidine 393856-17-2P, 2-Amino-5-(4-tert-butylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-21-8P, 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyphenylethylamino)pyrimidine 393856-24-1P, 2-Amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine 393856-26-3P, 2-Amino-5-(4-propylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-29-6P, 2-Amino-4-(4-hydroxy-2-methylanilino)-5-(4-chlorophenylethynyl)pyrimidine 393856-31-0P, 2-Amino-5-(4-chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine 393856-48-9P, 4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine 393856-51-4P, 5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine 393856-54-7P, 2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-(4-methylphenylethynyl)pyrimidine 393856-57-0P 393856-60-5P, 5-(4-Chlorophenylethynyl)-2-formamido-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-63-8P, 2-Amino-5-(3,4-dichlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-69-4P, 2-Amino-5-(2-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-73-0P, 2-Amino-5-(4-chlorophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine-0-dimethyl phosphate ester 393856-76-3P, 2-Amino-5-(4-chlorophenylethynyl)-4-(3,4-dimethoxyanilino)pyrimidine 393856-79-6P, 5-(4-Acetamidophenylethynyl)-2-amino-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393856-82-1P, 5-(4-Chlorophenylethynyl)-4-(trans-4-hydroxycyclohexylamino)pyrimidine 393856-85-4P, 2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-phenylethynylpyrimidine 393856-89-8P, 2-Amino-5-(4-chlorophenylethynyl)-4-(4-cis-hydroxycyclohexylamino)pyrimidine 393856-91-2P, 2-Amino-4-[2-(2-hydroxyethoxy)ethylamino]-5-phenylethynylpyrimidine 393856-95-6P, 2-Amino-5-(4-ethylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine 393857-11-9P, 5-(4-Chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-(trans-4-hydroxycyclohexylamino)pyrimidine 393857-13-1P, 2-Amino-5-(4-chlorophenylethynyl)-4-(2-hydroxyethylamino)pyrimidine

393857-31-3P, 2-Amino-5-(4-ethylphenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine hydrochloride 393857-34-6P, 2-Amino-5-(4-bromophenylethynyl)-4-(4-trans-hydroxycyclohexylamino)pyrimidine hydrochloride 393857-35-7P, 5-(4-Acetamidophenylethynyl)-2-amino-4-(4-trans-hydroxycyclohexylamino)pyrimidine hydrochloride 393857-41-5P, 2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-nitrophenylethynyl)pyrimidine hydrochloride 393857-43-7P, 2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-propylphenylethynyl)pyrimidine hydrochloride 393857-47-1P, 2-Amino-4-(4-hydroxyanilino)-5-(4-methoxyphenylethynyl)pyrimidine hydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CNS agent; preparation of (arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegenerative and other neurological disorders)

RN 393855-73-7 CAPLUS


CN Cyclohexanol, 4-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 393855-76-0 CAPLUS

CN Ethanol, 2-[2-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]ethoxy]- (CA INDEX NAME)



RN 393855-79-3 CAPLUS


CN Ethanol, 2-[2-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]ethoxy]- (CA INDEX NAME)



RN 393855-81-7 CAPLUS


CN Ethanol, 2-[2-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]ethoxy]- (CA INDEX NAME)

11/815,269




RN 393856-02-5 CAPLUS

CN Ethanol, 2-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 393856-04-7 CAPLUS

CN Ethanol, 2-[[2-amino-5-(2-phenylethynyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 393856-07-0 CAPLUS

CN Phenol, 4-[[2-amino-5-(2-phenylethynyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 393856-10-5 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-pentylphenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.


11/815,269



RN 393856-13-8 CAPLUS

CN Acetamide, N-[4-[[trans-4-(acetyloxy)cyclohexyl]amino]-5-[2-(4-chlorophenyl)ethynyl]-2-pyrimidinyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 393856-17-2 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-[4-(1,1-dimethylethyl)phenyl]ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 393856-21-8 CAPLUS


CN Phenol, 4-[2-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)

11/815,269



RN 393856-24-1 CAPLUS


CN Phenol, 4-[[2-amino-5-[2-(4-methoxyphenyl)ethynyl]-4-pyrimidinyl]amino]-
(CA INDEX NAME)



RN 393856-26-3 CAPLUS


CN Cyclohexanol, 4-[[2-amino-5-[2-(4-propylphenyl)ethynyl]-4-pyrimidinyl]amino]-, trans-
(CA INDEX NAME)

Relative stereochemistry.



RN 393856-29-6 CAPLUS


CN Phenol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-3-methyl-
(CA INDEX NAME)



11/815,269


RN 393856-31-0 CAPLUS

CN Phenol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-
(CA INDEX NAME)




RN 393856-48-9 CAPLUS

CN Phenol, 4-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 393856-51-4 CAPLUS

CN Phenol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 393856-54-7 CAPLUS

CN Ethanol, 2-[2-[[2-amino-5-[2-(4-methylphenyl)ethynyl]-4-pyrimidinyl]amino]ethoxy]- (CA INDEX NAME)




RN 393856-57-0 CAPLUS

CN Cyclohexanol, 4-[[[2-amino-5-[2-(4-methylphenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.


11/815,269



RN 393856-60-5 CAPLUS

CN Formamide, N-[5-[2-(4-chlorophenyl)ethynyl]-4-[(trans-4-hydroxycyclohexyl)amino]-2-pyrimidinyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 393856-63-8 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(3,4-dichlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 393856-69-4 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(2-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

11/815,269


Relative stereochemistry.



RN 393856-73-0 CAPLUS


CN Phosphoric acid, trans-4-[[2-amino-5-[(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]cyclohexyl dimethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 393856-76-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-(4-chlorophenyl)ethynyl]-N4-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 393856-79-6 CAPLUS

CN Acetamide, N-[4-[2-[2-amino-4-[(trans-4-hydroxycyclohexyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.


11/815,269



RN 393856-82-1 CAPLUS

CN Cyclohexanol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 393856-85-4 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 393856-89-8 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.

11/815,269



RN 393856-91-2 CAPLUS


CN Ethanol, 2-[2-[[2-amino-5-(2-phenylethynyl)-4-pyrimidinyl]amino]ethoxy]-
(CA INDEX NAME)



RN 393856-95-6 CAPLUS

CN Cyclohexanol, 4-[[[2-amino-5-[2-(4-ethylphenyl)ethynyl]-4-pyrimidinyl]amino]-, trans-
(CA INDEX NAME)

Relative stereochemistry.




RN 393857-11-9 CAPLUS

CN Methanamidamide, N'-[5-[2-(4-chlorophenyl)ethynyl]-4-[(trans-4-hydroxycyclohexyl)amino]-2-pyrimidinyl]-N,N-bis(1-methylethyl)-
(CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.

11/815,269



RN 393857-13-1 CAPLUS


CN Ethanol, 2-[[2-amino-5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 393857-31-3 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-ethylphenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1), trans- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 393857-34-6 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-bromophenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1), trans- (CA INDEX NAME)

Relative stereochemistry.

11/815,269




● HCl

RN 393857-35-7 CAPLUS

CN Acetamide, N-[4-[2-[2-amino-4-[(trans-4-hydroxycyclohexyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 393857-41-5 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-nitrophenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1), trans- (CA INDEX NAME)

Relative stereochemistry.

11/815,269




● HCl

RN 393857-43-7 CAPLUS

CN Cyclohexanol, 4-[[2-amino-5-[2-(4-propylphenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1), trans- (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 393857-47-1 CAPLUS

CN Phenol, 4-[[2-amino-5-[2-(4-methoxyphenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

- IT 393857-14-2P, 5-(4-Chlorophenylethynyl)-2-diisopropylaminomethyleneamino-4-(4-hydroxyanilino)pyrimidine
 393857-20-0P, 4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine
 hydrochloride 393857-23-3P, 5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine hydrochloride
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of (arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegenerative and other neurol. disorders)
- RN 393857-14-2 CAPLUS
 CN Methanimidamide, N'-[5-[2-(4-chlorophenyl)ethynyl]-4-[(4-hydroxyphenyl)amino]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (CA INDEX NAME)




- RN 393857-20-0 CAPLUS
 CN Phenol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

- RN 393857-23-3 CAPLUS
 CN Phenol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

11/815,269




● HCl

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2000:457043 CAPLUS
 DN 133:89537
 TI Preparation of 2,4-pyrimidinediamine derivatives as anticancer agents
 IN Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth
 PA AstraZeneca UK Limited, UK
 SO PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2352896	A1	20000706	CA 1999-2352896	19991220
	EP 1140860	A1	20011010	EP 1999-962375	19991220
	EP 1140860	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916590	A	20011023	BR 1999-16590	19991220
	JP 2002533446	T	20021008	JP 2000-591012	19991220
	AU 763091	B2	20030710	AU 2000-18743	19991220
	NZ 512118	A	20030829	NZ 1999-512118	19991220
	AT 277020	T	20041015	AT 1999-962375	19991220
	PT 1140860	T	20050131	PT 1999-962375	19991220
	ES 2228145	T3	20050401	ES 1999-962375	19991220
	CN 1285580	C	20061122	CN 1999-816278	19991220
	ZA 2001004413	A	20020829	ZA 2001-4413	20010529
	NO 2001003038	A	20010822	NO 2001-3038	20010619
	NO 319815	B1	20050919		
	MX 2001PA06575	A	20011203	MX 2001-PA6575	20010625
	US 6593326	B1	20030715	US 2001-868602	20010823
PRAI	GB 1998-28511	A	19981224		
	WO 1999-GB4325	W	19991220		
OS	MARPAT 133:89537				
IT	280582-47-0P, 4-Anilino-2-chloro-5-(2-phenylethynyl)pyrimidine				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)				
RN	280582-47-0 CAPLUS				
CN	4-Pyrimidinamine, 2-chloro-N-phenyl-5-(2-phenylethynyl)- (CA INDEX NAME)				




11/815,269

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:216714 CAPLUS
 DN 130:311761
 TI Inhibitors of dihydrofolate reductase: design, synthesis and antimicrobial activities of 2,4-diamino-6-methyl-5-ethynylpyrimidines
 AU Jones, Michael L.; Baccanari, David P.; Tansik, Robert L.; Boytos, Christine M.; Rudolph, Sharon K.; Kuyper, Lee F.
 CS Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
 SO Journal of Heterocyclic Chemistry (1999), 36(1), 145-148
 CODEN: JHTCAD; ISSN: 0022-152X
 PB HeteroCorporation
 DT Journal
 LA English
 IT 223672-35-3P 223672-43-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of diaminomethylethynylpyrimidines and their inhibition of dihydrofolate reductase)
 RN 223672-35-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-(2-cyclopentylethynyl)-6-methyl- (CA INDEX NAME)



RN 223672-43-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-methyl-5-(2-phenylethynyl)- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:338127 CAPLUS

DN 129:16136

OREF 129:3469a,3472a

TI 5-[α -(Substituted aryl)alkenyl- and alkynyl]-2,4-diaminopyrimidines
as pesticidesIN Henrie, Robert N., II; Peake, Clinton J.; Cullen, Thomas G.; Yeager,
Walter H.; Brown, Mary E.; Buser, John W.

PA FMC Corp., USA

SO PCT Int. Appl., 102 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820878	A1	19980522	WO 1996-US17748	19961111
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9676696	A	19980603	AU 1996-76696	19961111
PRAI	WO 1996-US17748	W	19961111		
OS	MARPAT 129:16136				
IT	189810-48-8 189810-49-9 189810-51-3				
	189810-66-0 189810-67-1				
	RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)				
	(5-[α -(substituted aryl)alkenyl- and alkynyl]-2,4- diaminopyrimidines as pesticides and acaricides)				
RN	189810-48-8 CAPLUS				
CN	2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclobutyl]ethynyl]-6- methyl- (CA INDEX NAME)				



RN 189810-49-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclobutyl]ethynyl]-6-
methyl- (CA INDEX NAME)

11/815,269




RN 189810-51-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclohexyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 189810-66-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-fluorophenyl)cyclopropyl]ethynyl]-6-methyl- (CA INDEX NAME)




RN 189810-67-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-methyl-5-[2-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]ethynyl]- (CA INDEX NAME)



IT 189810-50-2P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (5-[α -(substituted aryl)alkenyl- and alkynyl]-2,4-diaminopyrimidines as pesticides and acaricides)
 RN 189810-50-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclopentyl]ethynyl]-6-methyl- (CA INDEX NAME)



IT 207799-66-4P
 RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (5-[α -(substituted aryl)alkenyl- and alkynyl]-2,4-diaminopyrimidines as pesticides and acaricides)
 RN 207799-66-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 5-[2-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]ethynyl]-6-methyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:287177 CAPLUS

DN 126:343574

OREF 126:66821a

TI Preparation of 5-[ω -(substituted aryl)alkenylene- and -alkynylene]-2,4-diaminopyrimidines as pesticides

IN Henrie, II Robert N.; Peake, Clinton J.; Cullen, Thomas G.; Yeager, Walter H.; Brown, Mary E.; Buser, John W.

PA FMC Corp., USA

SO U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 241,083, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5622954	A	19970422	US 1995-398205	19950302
	US 5696259	A	19971209	US 1996-681032	19960722
PRAI	US 1994-241083	B2	19940511		
	US 1995-398205	A3	19950302		

OS MARPAT 126:343574


IT 189810-48-8P 189810-49-9P 189810-50-2P

189810-51-3P 189810-66-0P 189810-67-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of [(substituted aryl)alkenylene- and -alkynylene]pyrimidinediamines as pesticides)

RN 189810-48-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclopropyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 189810-49-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclobutyl]ethynyl]-6-methyl- (CA INDEX NAME)

11/815,269




RN 189810-50-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclopentyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 189810-51-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-chlorophenyl)cyclohexyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 189810-66-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-[1-(4-fluorophenyl)cyclopropyl]ethynyl]-6-methyl- (CA INDEX NAME)

11/815,269



RN 189810-67-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-5-[2-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]ethynyl]- (CA INDEX NAME)



L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1995:35265 CAPLUS

DN 122:160666

OREF 122:29617a,29620a

TI Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors

IN Bigham, Eric Cleveland; Reinhard, John Frederick, Jr.; Moore, Philip Keith; Babbedge, Rachel Cecilia; Knowles, Richard Graham; Nobbs, Malcolm Stuart; Bull, Donald

PA Wellcome Foundation Ltd., UK

SO PCT Int. Appl., 46 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414780	A1	19940707	WO 1993-GB2556	19931215
	W: AU, CA, CZ, JP, KR, KZ, NO, NZ, PL, RU, UA, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9457045	A	19940719	AU 1994-57045	19931215
	EP 674627	A1	19951004	EP 1994-902868	19931215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08504798	T	19960521	JP 1993-514909	19931215
	ZA 9309480	A	19950619	ZA 1993-9480	19931217
	US 5459158	A	19951017	US 1993-168246	19931217
PRAI	GB 1992-26377	A	19921218		
	GB 1993-3221	A	19930218		
	WO 1993-GB2556	W	19931215		
OS	MARPAT 122:160666				
IT	157924-50-0P 157924-51-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as neuronal NO synthase inhibitor)				
RN	157924-50-0 CAPLUS				
CN	2,4-Pyrimidinediamine, 5-[2-(4-methylphenyl)ethynyl]- (CA INDEX NAME)				




RN 157924-51-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-(2-phenylethynyl)- (CA INDEX NAME)



11/815,269

L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1982:582351 CAPLUS
DN 97:182351
OREF 97:30509a,30512a
TI Studies on pyrimidine derivatives. XXIX. Synthesis of pyrimidines fused
with five-membered heterocycles by cross-coupling of 5-iodopyrimidines
with phenylacetylene and styrene
AU Sakamoto, Takao; Kondo, Yoshinori; Yamanaka, Hiroshi
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Chemical & Pharmaceutical Bulletin (1982), 30(7), 2417-20
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 97:182351
IT 83410-47-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 83410-47-3 CAPLUS
CN 4-Pyrimidinamine, 2,6-dimethyl-5-(phenylethynyl)- (9CI) (CA INDEX NAME)



11/815,269

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

117.21

296.24

STN INTERNATIONAL LOGOFF AT 16:24:08 ON 24 SEP 2008